Accelerating the Progress of Kinase Inhibitors in Oncology Article 加快激酶抑制剂在肿瘤学领域的应用进程 The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…Danielle Pillsbury2024 年 5 月 20 日
Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials Publication Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials A FRIENDS OF CANCER RESEARCH WHITE PAPER The article explores the complex landscape of determining…Jim Gallagher2023 年 12 月 19 日
FDA Trends for Accelerated Drug Approvals in Oncology Indications Poster FDA Trends for Accelerated Drug Approvals in Oncology Indications The FDA has modified and increased expectations around data needed to support accelerated approvals in…Danielle Pillsbury2023 年 9 月 20 日
Adoption of PROs in Early Clinical Trials for Oncology Drugs: Challenges and Opportunities Poster Adoption of PROs in Early Clinical Trials for Oncology Drugs: Challenges and Opportunities Despite changes in regulatory expectations, adoption of PROs in early-phase oncology trials remains very low…Danielle Pillsbury2023 年 9 月 20 日
Using Modeling & Simulation to Develop a Dosing Regimen for a Bispecific Antibody for Pediatric Cancer Case Study Using Modeling & Simulation to Develop a Dosing Regimen for a Bispecific Antibody for Pediatric Cancer Bispecific antibodies are an emerging class of antibodies developed in recent years that provide new…Danielle Pillsbury2023 年 1 月 23 日
PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Case Study PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to…Jim Gallagher2022 年 4 月 11 日
什么是 FDA Project Optimus?它会如何影响肿瘤药物开发? 博客 什么是 FDA Project Optimus?它会如何影响肿瘤药物开发? Project Optimus is an initiative proposed by the U.S. Food and Drug Administration’s Oncology Center…Jim Gallagher2022 年 2 月 2 日
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus On-Demand Webinar 肿瘤药物开发人员应该从 FDA Project Optimus 中期待获得什么? 一直以来,肿瘤药物的剂量策略都以最大耐受剂量为重点。This…Jim Gallagher2022 年 1 月 13 日
PBPK Modeling of Antibody-Drug Conjugates – Concept and Application On-Demand Webinar 抗体-药物偶联物的 PBPK 模型 — 概念和应用 Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…Jim Gallagher2022 年 1 月 13 日
Developing Targeted Covalent Inhibitor Drugs: 3 Key Considerations Blog 开发靶向共价抑制剂药物:3关键考虑因素 Traditional mechanisms of drug action rely on the reversible, noncovalent interaction of a ligand with…Jim Gallagher2021 年 11 月 5 日